ProPhase Labs, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ProPhase Labs, Inc. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $41.00K, a 98.75% decline year-over-year.
- ProPhase Labs, Inc. stock issued during period, value, new issues for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $0.00.
- ProPhase Labs, Inc. stock issued during period, value, new issues for fiscal 2025 was $3.56M, a 53.15% decline from fiscal 2024.
- ProPhase Labs, Inc. stock issued during period, value, new issues for fiscal 2024 was $7.59M.
- ProPhase Labs, Inc. stock issued during period, value, new issues for fiscal 2015 was $1.56M, a 68.15% decline from fiscal 2014.
- ProPhase Labs, Inc. stock issued during period, value, new issues for fiscal 2014 was $4.91M, a 1005.86% increase from fiscal 2013.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | $41.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2026-03-31 | $41.00K 10-Q/A · filed 2026-07-09 | $321.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $3.56M 10-K · filed 2026-06-01 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $6.53M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-06-30 | $280.00K 10-Q · filed 2026-08-19 | $6.53M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-03-31 | $3.28M 10-Q/A · filed 2026-07-09 | $10.87M derived: sum of 4 quarters · filed 2026-07-09 |
| 2024-12-31 | $2.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $7.59M 10-K · filed 2026-06-01 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | |
| 2024-06-30 | $4.62M 10-Q · filed 2025-08-13 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | |
| 2015-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2018-08-20 | $1.56M 10-K/A · filed 2018-08-20 |
| 2015-09-30 | $1.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | |
| 2014-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-24 | $4.91M 10-K · filed 2017-02-24 |
| 2014-09-30 | $83.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | $5.16M derived: sum of 4 quarters · filed 2016-03-29 |
| 2014-06-30 | $3.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | $5.08M derived: sum of 4 quarters · filed 2016-03-29 |
| 2014-03-31 | $947.00K 10-Q · filed 2014-05-12 | $1.20M derived: sum of 4 quarters · filed 2016-03-29 |
| 2013-12-31 | $249.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-29 | $444.00K 10-K · filed 2016-03-29 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13 | |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-13 | |
| 2013-03-31 | $195.00K 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $1.07M 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |